However, the Lp-PLA2 activity levels obtained in the acute phase of STEMI are not associated with short- or long-term clinical endpoints, including mortality, myocardial infarction, stroke or target vessel revascularization. This evidence concerns the gene PLA2G7 and myocardial infarction.